DCLK3 and neoplasm: It is well documented that glycans on glycoproteins and glycolipids are altered in tumor cells (35), and it turns out that immune cells (especially DCs) express glycan-binding receptors, lectins among which C-type lectin receptors (CLR) (36–38).